Introduction: Hang Seng Pharmaceutical Co., Ltd. is a high-tech joint-stock enterprise. Its main investors are Heng Chang Investment, a subsidiary of Jiangsu Huachang Group, and Nanjing Ruihua Holdings. It has a management team proficient in internationalization and localization of pharmaceutical business at home and abroad, with more than 300 employees, which is in rapid development and transformation. The annual sales of the company's existing business is nearly 300 million yuan, and the new biomedical R&D and production projects being implemented (with a total investment of 350 million yuan) will promote the company to become an international-level pharmaceutical company that integrates standardized raw material procurement, technology research and development, cGMP manufacturing, access regulations and global marketing, and is mainly committed to value integration and technological innovation in the pharmaceutical industry for treating respiratory diseases and metabolic diseases. Business entities include manufacturing and research of yangtze river international Industrial Park in Zhangjiagang, Suzhou.

Legal Representative: Zhu.

Date of establishment: September 29, 2002

Registered capital: RMB100000 yuan.

Industrial and commercial registration number: 320592000000727

Enterprise type: limited liability company

Company address: Director of Jiangsu Yang Zijiang International Chemical Industrial Park, east of Jiang Lu and south of Huanghai Road.